Phase 1 Clinical Trial (original) (raw)
Latest News for: phase 1 clinical trial
Long term durability data from the vispa-cel ANTLER phase 1 clinical trial, EHA 2026 oral presentation (Caribou Biosciences Inc)
Public Technologies 11 Jun 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 132413384) .
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer ...
Nasdaq Globe Newswire 11 Jun 2026
– Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor durvalumab – ... .
Longer follow up data on dose escalation for CB-011 CaMMouflage phase 1 clinical trial, EHA 2026 oral presentation (Caribou Biosciences Inc)
Public Technologies 11 Jun 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 132413373) .
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research (Form 8-K) (Theriva Biologics Inc)
Public Technologies 11 Jun 2026
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research ... Data summary - VCN-01 Phase 1 clinical trial (NCT03799744) in ...
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
Caledonian Record 11 Jun 2026
APEX 24-week Phase 2 trial is evaluating the safety and ...
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
The Buffalo News 11 Jun 2026
The shipment of naturally derived psilocybin, ...
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial (Form 6-K) (Optimi Health Corp)
Public Technologies 10 Jun 2026
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial ... naturally derived psilocybin to the United Kingdom in support of a planned Phase 2 clinical trial.
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients (Form 8-K) (Tectonic Therapeutic Inc)
Public Technologies 10 Jun 2026
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients • ... "Reaching full enrollment in our APEX Phase 2 clinical trial represents a critical milestone ...
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the
Hastings Tribune 09 Jun 2026
LIBERTY clinical trial will evaluate the comparative ...
Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial
The Eagle-Tribune 08 Jun 2026
CRPS-RISE designed to support FDA regulatory submission for potential approval of neridronate in patients with CRPS-1FDA has previously granted neridronate with Breakthrough Therapy, Fast Track, and Orphan Drug designations ... .
Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate ...
Nasdaq Globe Newswire 08 Jun 2026
today announced that the first patient has been dosed in its pivotal CRPS-RISE ...
Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT® in Aggressive Brain Cancer (Glioblastoma)
PR Newswire 08 Jun 2026
A preliminary readout of the Phase 1 clinical trial with uTREAT® in glioblastoma, an aggressive brain cancer, has now been undertaken ... "The preliminary readout of our Phase 1 clinical trial with ...
Onchilles Pharma Doses First Patient in Phase 1/2 Clinical Trial of N17350 for Advanced Solid Tumors
Business Wire 04 Jun 2026
SAN DIEGO--(BUSINESS WIRE)-- #ELANE--Onchilles Pharma Doses First Patient in Phase 1/2 Clinical Trial of N17350 for Advanced Solid Tumors ... .
Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10
PR Newswire 04 Jun 2026
SHENZHEN, China, June 4, 2026 /PRNewswire/ -- Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently ...
Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial ...
Canada Newswire 04 Jun 2026
SHENZHEN, China, June 4, 2026 /CNW/ -- Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd.